Severe Hypophosphatemia Following Denosumab Administration in a Hemodialysis Patient with Progressive Prostate Cancer

In a 68-year-old man on maintenance hemodialysis (HD), severe anemia was detected. Bone marrow biopsy was performed for investigation of pancytopenia and pathological examination revealed adenocarcinoma of the prostate. Prostate specific antigen (PSA) was 574 ng/mL. After androgen deprivation therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Masuda, Hiroshi, Kaga, Kanya, Inahara, Masahiko, Araki, Kazuhiro, Kojima, Satoko, Naya, Yukio, Takano, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408148/
https://www.ncbi.nlm.nih.gov/pubmed/28462158
http://dx.doi.org/10.1016/j.eucr.2016.11.019
_version_ 1783232245931180032
author Masuda, Hiroshi
Kaga, Kanya
Inahara, Masahiko
Araki, Kazuhiro
Kojima, Satoko
Naya, Yukio
Takano, Makoto
author_facet Masuda, Hiroshi
Kaga, Kanya
Inahara, Masahiko
Araki, Kazuhiro
Kojima, Satoko
Naya, Yukio
Takano, Makoto
author_sort Masuda, Hiroshi
collection PubMed
description In a 68-year-old man on maintenance hemodialysis (HD), severe anemia was detected. Bone marrow biopsy was performed for investigation of pancytopenia and pathological examination revealed adenocarcinoma of the prostate. Prostate specific antigen (PSA) was 574 ng/mL. After androgen deprivation therapy was initiated, PSA decreased to 13.7 ng/mL. But subsequent elevation of PSA and pain due to bone metastases were recognized. Denosumab (120 mg) was administered. Although improvement of bone pain was observed, severe hypocalcemia occurred. Severe hypophosphatemia was subsequently detected. When we use denosumab in dialysis patients with advanced cancer, we should be careful of hypophosphatemia.
format Online
Article
Text
id pubmed-5408148
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-54081482017-05-01 Severe Hypophosphatemia Following Denosumab Administration in a Hemodialysis Patient with Progressive Prostate Cancer Masuda, Hiroshi Kaga, Kanya Inahara, Masahiko Araki, Kazuhiro Kojima, Satoko Naya, Yukio Takano, Makoto Urol Case Rep Oncology In a 68-year-old man on maintenance hemodialysis (HD), severe anemia was detected. Bone marrow biopsy was performed for investigation of pancytopenia and pathological examination revealed adenocarcinoma of the prostate. Prostate specific antigen (PSA) was 574 ng/mL. After androgen deprivation therapy was initiated, PSA decreased to 13.7 ng/mL. But subsequent elevation of PSA and pain due to bone metastases were recognized. Denosumab (120 mg) was administered. Although improvement of bone pain was observed, severe hypocalcemia occurred. Severe hypophosphatemia was subsequently detected. When we use denosumab in dialysis patients with advanced cancer, we should be careful of hypophosphatemia. Elsevier 2017-04-26 /pmc/articles/PMC5408148/ /pubmed/28462158 http://dx.doi.org/10.1016/j.eucr.2016.11.019 Text en © 2016 Published by Elsevier Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Oncology
Masuda, Hiroshi
Kaga, Kanya
Inahara, Masahiko
Araki, Kazuhiro
Kojima, Satoko
Naya, Yukio
Takano, Makoto
Severe Hypophosphatemia Following Denosumab Administration in a Hemodialysis Patient with Progressive Prostate Cancer
title Severe Hypophosphatemia Following Denosumab Administration in a Hemodialysis Patient with Progressive Prostate Cancer
title_full Severe Hypophosphatemia Following Denosumab Administration in a Hemodialysis Patient with Progressive Prostate Cancer
title_fullStr Severe Hypophosphatemia Following Denosumab Administration in a Hemodialysis Patient with Progressive Prostate Cancer
title_full_unstemmed Severe Hypophosphatemia Following Denosumab Administration in a Hemodialysis Patient with Progressive Prostate Cancer
title_short Severe Hypophosphatemia Following Denosumab Administration in a Hemodialysis Patient with Progressive Prostate Cancer
title_sort severe hypophosphatemia following denosumab administration in a hemodialysis patient with progressive prostate cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408148/
https://www.ncbi.nlm.nih.gov/pubmed/28462158
http://dx.doi.org/10.1016/j.eucr.2016.11.019
work_keys_str_mv AT masudahiroshi severehypophosphatemiafollowingdenosumabadministrationinahemodialysispatientwithprogressiveprostatecancer
AT kagakanya severehypophosphatemiafollowingdenosumabadministrationinahemodialysispatientwithprogressiveprostatecancer
AT inaharamasahiko severehypophosphatemiafollowingdenosumabadministrationinahemodialysispatientwithprogressiveprostatecancer
AT arakikazuhiro severehypophosphatemiafollowingdenosumabadministrationinahemodialysispatientwithprogressiveprostatecancer
AT kojimasatoko severehypophosphatemiafollowingdenosumabadministrationinahemodialysispatientwithprogressiveprostatecancer
AT nayayukio severehypophosphatemiafollowingdenosumabadministrationinahemodialysispatientwithprogressiveprostatecancer
AT takanomakoto severehypophosphatemiafollowingdenosumabadministrationinahemodialysispatientwithprogressiveprostatecancer

Ejemplares similares